Isolation and analysis of cell-free fetal DNA from maternal peripheral blood in Chinese women.

Journal: Genetics and molecular research : GMR
PMID:

Abstract

Non-invasive prenatal diagnosis is used to detect the genetic material of the fetus by isolating the cell-free fetal DNA (cffDNA) from maternal peripheral blood. In order to establish an isolation method for cffDNA from maternal peripheral blood in Chinese women, the cffDNA was acquired with a two-step centrifugation using a QlAamp DNA Blood mini kit. The SRY gene of plasma DNA was amplified by polymerase chain reaction (PCR). Real-time quantitative PCR was used to measure the concentration of cffDNA in maternal peripheral blood in different pregnant women. The results of the SRY gene amplification of plasma DNA from pregnant women was the same as that of the amniocyte DNA. The average concentration of cffDNA in maternal peripheral blood of pregnant women in different gestational stages was 0.98 ng/mL (0.26-1.49 ng/mL), 1.43 ng/mL (0.46- 2.34 ng/mL), and 1.95 ng/mL (0.65-6.81 ng/mL) from early, middle, and late gestational stages, respectively. The mean of cffDNA from total DNA in plasma in different stages of gestation was 22.28% (9.86-27.81%). The lowest concentration of DNA amplified by nested-PCR in our research was 10-4-10-3 ng/μL. The isolation method for cffDNA from maternal peripheral blood was successfully established and further research into its applications will be conducted.

Authors

  • W C Yang
    Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Sichuan Medical University, Luzhou City, Sichuan Province, China.
  • L Zhu
    Department of Infectious Diseases, Beijing Children's Hospital, Beijing, China.
  • Y M Qiu
    Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Sichuan Medical University, Luzhou City, Sichuan Province, China.
  • B X Zhou
    Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Sichuan Medical University, Luzhou City, Sichuan Province, China.
  • J L Cheng
    Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Sichuan Medical University, Luzhou City, Sichuan Province, China.
  • C L Wei
    Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Sichuan Medical University, Luzhou City, Sichuan Province, China.
  • H C Chen
    Department of Biochemistry, School of Life Sciences & the State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan Province, China.
  • L Y Li
    Institute of Reproduction and Stem Cell Engineering, Central South University Xiangya School of Medicine, Changsha, Hunan Province, China.
  • X D Fu
    Department of Obstetrics and Gynecology, First Affiliated Hospital of Sichuan Medical University, Luzhou, Sichuan Province, China.
  • J J Fu
    Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Sichuan Medical University, Luzhou City, Sichuan Province, China.